Figures & data
Table 1. Characteristics of propensity-score matched rivaroxaban and warfarin patients experiencing an index deep vein thrombosis of pulmonary embolism.
Table 2. Cumulative 12-month per patient post-venous thromboembolism costs.
Table 3. Cumulative 12-month per patient post-deep vein thrombosis costs.
Table 4. Cumulative 12-month per patient post-pulmonary embolism costs.